Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics

Published: Saturday, June 28, 2014
Last Updated: Saturday, June 28, 2014
Bookmark and Share
Big data approach bridges the gap between genomics and personalized medicine.

Definiens AG which offers a unique approach to tissue diagnostics aimed at helping physicians improve treatment said that it has closed a round of financing for € 15 Million. The round was led by Wellington Partners, a leading pan-European venture capital firm.

Gilde Healthcare co-led the financing round and was joined by the other existing investors Cipio Partners and TVM Capital in the financing. In conjunction with the financing, Dr. Rainer Strohmenger, General Partner and Managing Director for Wellington, will join Definiens' Board of Directors.

The new funds will allow Definiens to grow its global business in digital pathology image analysis and expand into digital tissue diagnostics. Major investments will be made in executing the company’s Tissue Phenomics strategy, enabling partnerships with leading medical centers and pharmaceutical companies to advance the diagnosis and treatment of cancer.

Tissue Phenomics is based on Definiens' proprietary Cognition Network Technology®, invented by Nobel laureate and founder Prof. Gerd Binnig and involves a unique big data approach to develop new tissue-based diagnostic tests for oncology and immunotherapy.

Using these new diagnostic tests will allow for better prediction of patient outcomes and identification of drug responders, thereby bridging the gap between genomic data and cancer outcomes.

Dr. Rainer Strohmenger, General Partner and Managing Director at Wellington Partners, commented: “We have been following Definiens for many years and have always been impressed by the visionary concept and exciting technology the company has. We believe that Definiens now is approaching an inflection point which will have a significant impact on the growth potential and strategic value of this business for the leading players in imaging, diagnostics and oncology drug development.”

Thomas Heydler, CEO at Definiens, stated: “Wellington Partners is one of the few investors experienced in both diagnostics and healthcare IT with a strong track record of successfully building and capturing value from businesses in these areas. We are honored to add Wellington to our investor base and welcome Dr. Strohmenger to our Board of Directors. This financing will allow us to pursue our aggressive growth strategy to further expand our global leadership in Tissue Phenomics.”

Dr. Gerald Möller, Chairman at Definiens AG, added: “The use of state-of-the-art information technology in medicine will dramatically improve the way patients will be diagnosed and treated and the way new drugs and diagnostic tests will be developed. This change will not only lead to improved patient outcomes but also drive personalized medicine forward, and I am convinced that Definiens will play an important role in accelerating this change, especially in the fields of pathology, cancer, and immunotherapy. The fact that we have attracted this significant financing with new lead investor Wellington is another confirmation of Definiens’ strong position.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Indivumed, Definiens Partner
Partnership aims to unlock the power of tumor tissue for drug discovery and development.
Wednesday, July 20, 2016
Definiens Expands Management Team to Develop the Clinical Market
Company announces appointment of Pablo Jordan and Rebecca Berghorn.
Tuesday, October 29, 2013
Definiens Appoints Chief Marketing Officer, Merrilyn Datta, Ph.D.
Dr. Datta brings a wealth of experience in marketing and her expertise will be critical as Definiens expands its leadership in the life sciences and tissue diagnostics industries.
Tuesday, April 09, 2013
Definiens Establishes Advisory Board
Renowned industry experts to advise Definiens on clinical digital pathology market.
Thursday, March 28, 2013
Definiens Strengthens Leadership with Key Appointment
Former Aperio executive and digital pathology market expert, Dr. Martin Stuart, joins executive team.
Thursday, February 02, 2012
Definiens Image Analysis Technology Improves Accuracy in Scoring Her2/neu in Breast Cancer Biopsies
New multi-dimensional image analysis platform aids diagnosis and treatment of breast cancer.
Wednesday, June 03, 2009
Scientific News
Molecular Alarm Clock Wakes Resting Ovules
Study of fruit flies yields discovery of a molecular "alarm clock" that activates resting ovules.
Improved Immunity in Older Age
A study from Oxford and Basel universities may point the way to maintaining our immune systems as we get older.
Neurodvelopmental Disorder Cause Linked to SON Gene
A genetic link has been discovered for a previously unxplained neurodevelopmental disorder.
Russian TB Thrives Within Macrophages
MIPT researchers have identified features of mycobacterium tuberculosis strains that may explain their success.
Gene Linked to Hearing Loss Identified
Researchers have identifed a gene associated with age-related hearing loss.
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
Personalised Medicine: Dose by Design
Personalised medicine holds the promise of a new approach to healthcare, tailored exactly to our individual needs, as Congenica's Nick Lench discussed on a recent BBC Radio 4 programme.
Misdiagnosis in HCM Tests
Genetic tests for potentially fatal heart anomaly can misdiagnose condition in black Americans.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
Brain Area with Active ALS Gene Identified
Expression sites in the brain have been identified for a gene which is associated with Motor Neuron Disease.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!